GH axis Research Market

Hexarelin

A growth hormone secretagogue and ghrelin-receptor agonist that remains a familiar legacy name in GH-peptide stacks.

Growth HormoneGhrelin ReceptorSecretagogueResearch Market

Also appears in: Hormone

Vial price compare
26 tracked offers across 26 vendors · 9 dosages
Best trust-adjusted value: Peptuvia · Strong trust · $1.93/mg
From
$1.93/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

Flat vs. Oct 7
Current low$1.93/mg
Market median$9.00/mg
Current coverage18 vendors
Observed window90 daily points
Lowest effective price Market median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the latest vendor-default policy recorded for that UTC day. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Hexarelin crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence 22 certificate records for Hexarelin products, from 14 vendors 6 reference a report on the testing laboratory's own system · 5 have a laboratory lookup that answered when last checked · 20 match a vendor product page at the same address
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
GH axis / secretagogue research

Primary research area: GH axis. Also surfaces under Hormone for browsing and discovery.

Body systems
Hormones · Muscle & bone

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
0

No major aliases are tracked for this profile yet.

Signal depth
Low

No FDA label signal · 0 trials · 291 PubMed results

Preclinical
Research evidence

Current evidence for Hexarelin is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Hexarelin has no clinical trials that name it and 291 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
High-impact
The Journal of Clinical Endocrinology & Metabolism · 516 citations Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatural Peptidyl GHS, and GH-Releasing Hormone1 The Journal of Clinical Endocrinology & Metabolism · 163 citations Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man Journal Article Histopathological and immunohistochemical characterization of MPTP-associated pancreatic injury and its attenuation by Hexarelin in mice. Journal Article Protective and restorative effects of hexarelin on MPTP-induced lung injury in mice. Journal Article The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Journal Article Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-02 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What hexarelin is

Hexarelin is a growth hormone secretagogue and ghrelin-receptor agonist that predates many of the newer GH-related peptide stacks now discussed online.

Why it matters

It belongs in the library because it is still a recognizable legacy name alongside compounds like GHRP-2, GHRP-6, and ipamorelin.

Regulatory context

Hexarelin is not FDA approved for routine consumer therapeutic use in the United States. It fits best in the research-market category.

Practical reading note

Hexarelin helps show the older side of the GH-secretagogue ecosystem, which is useful context when newer peptides get marketed as if they appeared from nowhere.